Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer

Vinorelbine Plus Gemcitabine (VG) Versus Vinorelbine Plus Carboplatin (VC) in Advanced Non-small Cell Lung Cancer. An Open Randomized Multicenter Phase III Trial From Norwegian Lung Cancer Study Group (NLCG)

The purpose of this study is to explore if the combination of vinorelbine and gemcitabine is better than vinorelbine and carboplatin in the treatment of advanced non-small cell lung cancer, in terms of survival, quality of life and need for palliative radiotherapy.

Inclusion Criteria:

• Non-small cell lung cancer stage IIIB or IV
• Not eligible for radical radiotherapy or surgery
• WHO performance status 0-2

Exclusion Criteria:

• Pregnancy
• Other clinical active cancer disease
• ALAT/ALP more than 3 times upper normal limit, bilirubin >1.5 upper limit
• Bowel disease that causes malabsorption